A Phase I/II Study of Ramucirumab in Children and Young Adults with Desmoplastic Small Round Cell Tumor


Full Title

CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research (COG ADVL2021)


The purpose of this study is to see if adding ramucirumab to standard chemotherapy for  desmoplastic small round cell tumor (DSRCT) is more effective than standard chemotherapy alone in children and young adults whose cancers came back or continued to grow despite prior therapy. Patients will be randomly assigned to receive cyclophosphamide and vinorelbine with or without ramucirumab.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have DSCRT that has come back or continued to grow despite previous therapy
  • At least 1 week must pass since the completion of prior treatments and receipt of the study therapy.
  • This study is for people ages 12-29.

For more information and to ask about eligibility for this study, please contact 833-MSK-KIDS.